Basic Information
| LncRNA/CircRNA Name | DANCR |
| Synonyms | NA |
| Region | GRCh38_4:52712404-52720351 |
| Ensemble | ENSG00000226950 |
| Refseq | NR_024031 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qRT-PCR, Western blot |
| Sample | HCC tissues,cell lines |
| Expression Pattern | up-regulated |
| Function Description | the role of DANCR relied largely on the association with PSMD10. DANCR stabilized PSMD10 mRNA through blocking the repressing effect of several microRNAs on PSMD10. Besides, DANCR activated IL-6/STAT3 signaling via PSMD10. Furthermore, we revealed that DANCR transcription was enhanced by the activation of IL-6/STAT3 signaling, indicating a positive feedback loop of DANCR and IL-6/STAT3 signaling. |
| Pubmed ID | 32103983 |
| Year | 2020 |
| Title | LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma Cells |
External Links
| Links for DANCR | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |